-

ICON 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against ICON plc - ICLR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 11, 2025 to file lead plaintiff applications in securities class action lawsuits against ICON plc (the “Company”) (NasdaqGS: ICLR), if they purchased the Company’s shares between July 27, 2023 and January 13, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Eastern District of New York.

What You May Do

If you purchased shares of ICON and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-iclr/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by April 11, 2025.

About the Lawsuit

ICON and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On October 23, 2024, the Company reported financial results for 3Q 2024, disclosing quarterly revenues of just $2.03 billion, revealing a shocking “revenue shortfall” that significantly missed consensus estimates of $2.13 billion by more than $100 million, that quarterly net new business wins had declined sequentially to $2.3 billion during the quarter, and that its book-to-bill ratio fell sequentially to 1.15, down from 1.22 in the prior quarter, due to ongoing cost containment measures by customers. On this news, the price of ICON’s shares fell from $280.76 per share on October 23, 2024 to $220.47 per share on October 25, 2024. Then, on January 14, 2025, the Company disclosed financial guidance for 2025 well below analysts’ expectations due to “trial activity [that] has been impacted by cautious spending from biopharma customers” and “a headwind from our top two customers.” On this news, the price of ICON’s shares fell from $217.99 per share on January 13, 2025, to $200.24 per share on January 14, 2025.

The first-filed case is Shing v. ICON plc, No. 25-cv-00763. A subsequent case, Police and Fire Retirement System of the City of Detroit v. ICON plc, No. 25-cv-1807, updated the Class Period.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

Kahn Swick & Foti, LLC

NASDAQ:ICLR

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

More News From Kahn Swick & Foti, LLC

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of...

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contin...

McCormick & Co Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of McCormick & Company, Incorporated - MKC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of McCormick & Company, Incorporated (NYSE: MKC) and Unilever PLC’s (NYSE: UL) Foods business (excluding India and other excluded businesses). Under the terms of the merger agreement, upon closing of the proposed transaction, McCormick shareholders will own 35.0% of the combined company. KSF is seeking to d...
Back to Newsroom